SecBot SecBot
Biotech Drug Report Generated Nov 15, 2026

MGC028

MGNX·MacroGenics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1
Time to market
If MGC028 advances successfully through Phase 1 dose optimization and into Phase 2/3 trials, potential approval would be several years away, likely 2029 or later under an optimistic scenario. The drug is currently in Phase 1 dose optimization.
Why 3/10
MGC028 is a Phase 1 ADC with no scheduled hard binary catalyst (PDUFA, pivotal readout, or AdComm) in the next 12 months. The Phase 1 dose escalation recently completed and interim results were presented at ESMO 2026. The next milestone is maturation of the ongoing dose optimization cohort(s), with no specified date. MGC028 is one of several preclinical/Phase 1 assets at MacroGenics and is not the company's lead program. Per the rubric, a Phase 1 asset with no scheduled binary catalyst scores below 5.
Actionable Insight NEUTRAL

MGC028 is now in dose optimization after completing Phase 1 dose escalation. The next data readout could come in 2027 once both dose-level cohorts mature, but no date is set. Interim results were already presented at ESMO 2026; the market reaction to those data was not a major stock mover since MGC028 is one of several early-stage assets at MacroGenics. Watch for any future clinical update or partnership interest around the ADAM9 target.

Price Chart

Loading chart...

Executive Summary

MGC028 is an early-stage antibody-drug conjugate (ADC) targeting ADAM9, a protein overexpressed in several cancers, being developed by MacroGenics (NASDAQ: MGNX). It uses a Topoisomerase 1 inhibitor payload, the same drug class used in several approved ADCs. As of November 2026, the Phase 1 first-in-human dose-escalation study has been completed and interim results were presented at ESMO 2026. The company selected a lead indication and is now performing dose optimization across two dose levels. MGC028 is one of several pipeline programs at MacroGenics, which also includes MGC026 (B7-H3 ADC, mid-2027 update), MGC030 (Phase 1 just started), and lorigerlimab (Phase 2). With no approved products, MacroGenics trades at approximately $2.20 per share with a ~$148M market cap, below its $287M cash position, implying the pipeline has negative enterprise value. No hard binary catalyst is scheduled for MGC028 in the next 12 months.

How It Works

MGC028 is an antibody-drug conjugate (ADC), a type of precision cancer therapy. It works like a guided missile: the antibody portion targets a protein called ADAM9 found on the surface of many cancer cells (including pancreatic, lung, and gastric cancers). When the antibody binds to ADAM9, the cancer cell internalizes the drug, and a chemotherapy payload (a Topoisomerase 1 inhibitor) is released inside the cell to kill it. The Topo1 inhibitor class is the same mechanism used in several approved ADCs including Enhertu and Trodelvy.

Trial Status

Phase 1 first-in-human dose escalation completed. Interim results presented at ESMO 2026. Selected lead indication for dose optimization across two dose levels. No specific next-readout date has been announced.

The Two-Sided Case

▲ Bull Case5
ADAM9 is overexpressed in multiple high-incidence cancers (pancreatic, gastric, lung adenocarcinoma, squamous-cell lung cancer), offering a large addressable patient population if the drug works.
MGC028 uses a Topo1 inhibitor payload, the same class as Enhertu and Trodelvy (both billion-dollar ADCs), potentially offering a favorable efficacy/toxicity profile.
Phase 1 dose escalation completed successfully with a lead indication selected for dose optimization, suggesting tolerable safety and early signs of activity.
MacroGenics has $287.7M in cash providing runway through 2028, reducing near-term dilution risk while MGC028 and other pipeline assets advance.
The stock trades at $2.20 with a $148M market cap, below the cash position alone (~$287M cash implies ~$5.15/share in cash value), giving the pipeline effectively negative enterprise value.
▼ Bear Case5
MGC028 is still in early Phase 1 (dose optimization), many years from potential approval; the vast majority of Phase 1 ADCs fail or are deprioritized.
MacroGenics has no approved products and depends on partnership revenue, which is lumpy (Q3 2026 revenue fell to $18.7M from $53M a year ago).
The ADAM9 target is not clinically validated; no ADAM9-directed ADC has been approved, creating biological uncertainty.
MGC028 is just one of several early-stage pipeline programs (MGC026, MGC030, lorigerlimab); a setback at the company level could reduce resources for this asset.
Competing ADCs against more validated targets (B7-H3, HER2, Trop-2) from larger companies could crowd out interest in an unproven target like ADAM9.

Upcoming Catalysts

  • Updated Phase 1 dose optimization data (timing unspecified)
  • Possible selection of a specific tumor indication for Phase 2 expansion
  • Broader MacroGenics catalysts: MGC026 data update mid-2027, MGC030 Phase 1 enrollment updates, lorigerlimab Phase 2 CCGC update H1 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

MacroGenics, Inc. PRESS-RELEASE MGNX ·Originating report

Sources · 7

Hover a chip for the title
1 markets.businessinsider.com2 manilatimes.net3 theglobeandmail.com4 uk.investing.com5 nasdaq.com6 seekingalpha.com7 sec.gov